Avectas is an Ireland-based cell engineering technology company developing a unique intracellular delivery platform to enable ex vivo cell-based therapies. The company’s SOLUPORE™ technology is an efficient, non-viral cell engineering solution that allows efficient transfer of cargo into cells while maintaining very high levels of cell viability and functionality.
The team at Avectas was preparing its technology for commercialization and required its non-viral cell engineering platform, SOLUPORE™, to be assessed by an experienced third party. Avectas requested support from CCRM, a Canadian centre of excellence in cell and gene therapy and a reliable partner to extend their development capacity and capabilities. CCRM also had the advantage of offering proximity to a large number of potential adopters of the SOLUPORE™ technology.
Avectas was looking to accelerate the translation of SOLUPORE™ into the clinic.